Natera Inc (NASDAQ:NTRA) was the recipient of a significant drop in short interest in July. As of July 31st, there was short interest totalling 3,093,800 shares, a drop of 27.5% from the June 30th total of 4,267,100 shares. Approximately 6.6% of the shares of the company are short sold. Based on an average daily volume of 717,000 shares, the short-interest ratio is currently 4.3 days.

Natera stock traded up $0.37 during mid-day trading on Tuesday, hitting $29.68. 622,706 shares of the company traded hands, compared to its average volume of 687,822. Natera has a one year low of $11.08 and a one year high of $33.25. The firm has a market capitalization of $2.25 billion, a PE ratio of -13.80 and a beta of 1.51. The company has a current ratio of 1.85, a quick ratio of 1.73 and a debt-to-equity ratio of 20.88. The business’s fifty day moving average price is $27.13.

Natera (NASDAQ:NTRA) last announced its earnings results on Wednesday, August 7th. The medical research company reported ($0.48) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.09. Natera had a negative net margin of 46.78% and a negative return on equity of 409.49%. The business had revenue of $74.36 million during the quarter, compared to analyst estimates of $66.77 million. During the same period in the previous year, the business posted ($0.62) earnings per share. Natera’s revenue for the quarter was up 17.9% on a year-over-year basis. As a group, sell-side analysts forecast that Natera will post -2.1 EPS for the current fiscal year.

In related news, insider Jonathan Sheena sold 1,033 shares of the business’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $24.79, for a total transaction of $25,608.07. Following the completion of the transaction, the insider now owns 240,061 shares of the company’s stock, valued at $5,951,112.19. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Steven Leonard Chapman sold 98,996 shares of the business’s stock in a transaction that occurred on Friday, August 9th. The shares were sold at an average price of $33.00, for a total transaction of $3,266,868.00. Following the transaction, the chief executive officer now directly owns 20,061 shares of the company’s stock, valued at approximately $662,013. The disclosure for this sale can be found here. Insiders sold 398,261 shares of company stock valued at $12,516,321 in the last quarter. Corporate insiders own 9.29% of the company’s stock.

Institutional investors have recently made changes to their positions in the business. Jennison Associates LLC raised its holdings in Natera by 24.4% during the 2nd quarter. Jennison Associates LLC now owns 4,434,727 shares of the medical research company’s stock valued at $122,310,000 after buying an additional 869,420 shares during the last quarter. FMR LLC boosted its stake in Natera by 57.0% in the 4th quarter. FMR LLC now owns 3,908,921 shares of the medical research company’s stock worth $54,568,000 after purchasing an additional 1,419,390 shares in the last quarter. Wells Fargo & Company MN boosted its stake in Natera by 1,149.5% in the 2nd quarter. Wells Fargo & Company MN now owns 1,199,174 shares of the medical research company’s stock worth $33,074,000 after purchasing an additional 1,103,205 shares in the last quarter. Allianz Asset Management GmbH boosted its stake in Natera by 4.5% in the 2nd quarter. Allianz Asset Management GmbH now owns 589,036 shares of the medical research company’s stock worth $16,246,000 after purchasing an additional 25,334 shares in the last quarter. Finally, Kornitzer Capital Management Inc. KS lifted its stake in Natera by 64.2% during the 1st quarter. Kornitzer Capital Management Inc. KS now owns 513,141 shares of the medical research company’s stock valued at $10,581,000 after acquiring an additional 200,550 shares during the period. Institutional investors and hedge funds own 83.52% of the company’s stock.

Several equities analysts recently commented on the stock. Zacks Investment Research raised shares of Natera from a “sell” rating to a “hold” rating in a research note on Friday. BidaskClub raised shares of Natera from a “hold” rating to a “buy” rating in a research note on Friday. Piper Jaffray Companies boosted their price objective on shares of Natera from $28.00 to $32.00 and gave the company an “overweight” rating in a research note on Thursday, August 8th. Craig Hallum lifted their target price on shares of Natera from $29.00 to $37.00 and gave the company a “buy” rating in a research report on Thursday, August 8th. Finally, Canaccord Genuity lifted their target price on shares of Natera from $32.00 to $36.00 and gave the company a “buy” rating in a research report on Thursday, August 8th. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $32.29.

About Natera

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Read More: What is the Rule of 72?

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.